Skip to main content

Advertisement

SpringerLink
Log in

Small Bowel Dysmotility, Pseudoobstruction, and Functional Correlation with Histopathology: Lessons Learned

  • Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract (S Rao, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Small bowel dysmotility is a broad heterogeneous term that encompasses a wide range of gastrointestinal disorders resulting from abnormal gut motility. Chronic intestinal pseudo-obstruction (CIPO) is a severe, rare, and complex small bowel motility disorder at the extreme end of this spectrum. It is characterized by failure of the intestinal tract to propel contents, which results in signs and symptoms of bowel obstruction albeit in the absence of any obstructive lesion(s). In this article, we discuss up-to-date diagnostic techniques, management options, and histopathological findings in CIPO.

Recent Findings

We will emphasize the latest diagnostic methodologies and therapeutic options as well as enteric histopathologic abnormalities in patients with CIPO.

Summary

CIPO continues to be a clinical challenge. Several novel pharmacological agents hold promise including gastrointestinal hormone agonists and prokinetics. Furthermore, histopathologic findings may help guide therapy and provide further prognostic significance. At present, nutritional support, symptom management, and avoidance of long-term complications are the mainstay of treatment in CIPO.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Boeckxstaens G, Camilleri M, Sifrim D, Houghton LA, Elsenbruch S, Lindberg G, et al. Fundamentals of neurogastroenterology: physiology/motility - sensation. Gastroenterology. 2016;150:1292–1304.e2.

    Article  Google Scholar 

  2. Goldstein A, Hofstra R, Burns A. Building a brain in the gut: development of the enteric nervous system. Clin Genet. 2013;83:307–16.

    Article  CAS  PubMed  Google Scholar 

  3. Takahashi T. Mechanism of interdigestive migrating motor complex. J Neurogastroenterol Motil. 2012;18:246–57.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Wood JD. Enteric nervous system: neuropathic gastrointestinal motility. Dig Dis Sci. 2016;61. United States:1803–16.

    Article  PubMed  Google Scholar 

  5. Dudley HA, Sinclair IS, Mc LI, et al. Intestinal pseudo-obstruction. J R Coll Surg Edinb. 1958;3:206–17.

    CAS  PubMed  Google Scholar 

  6. Research Group for the Survey of the Actual Conditions of the Epidemiology, Diagnosis and Treatment of CIIP in Japan. Research Report, Fiscal Year. Research Project for Overcoming Intractable Diseases, Health Labour Sciences Research Grant, vol. 2009. Yokohama: San-ou Printing Ltd.; 2009. p. 3–6.

    Google Scholar 

  7. Iida H, Ohkubo H, Inamori M, et al. Epidemiology and clinical experience of chronic intestinal pseudo-obstruction in Japan: a nationwide epidemiologic survey. J Epidemiol. 2013;23:288–94.

    Article  PubMed  PubMed Central  Google Scholar 

  8. •• Paine P, McLaughlin J, Lal S. Review article: the assessment and management of chronic severe gastrointestinal dysmotility in adults. Aliment Pharmacol Ther. 2013;38:1209–29. This article suggests a management algorithm for patients with severe GI dysmotility after reviewing 721 relevant articles.

    Article  CAS  PubMed  Google Scholar 

  9. •• De Giorgio R, Sarnelli G, Corinaldesi R, et al. Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. Gut. 2004;53:1549–52. A comprehensive review on enteric neuropathies of the enteric system with recommended immunosuppressive therapies.

    Article  PubMed  PubMed Central  Google Scholar 

  10. •• Knowles CH, Giorgio RD, Kapur RP, et al. The London Classification of gastrointestinal neuromuscular pathology: report on behalf of the Gastro 2009 International Working Group. 2010;59(7):882–7. A structured classification system on histopathological phenotypes of gastrointestinal neuromuscular pathology as well as a a consensus report on technical aspects (i.e. safe tissue acquisition and processing).

  11. Cogliandro RF, Antonucci A, De Giorgio R, et al. Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders. Neurogastroenterol Motil. 2011;23:1084–91.

    Article  CAS  PubMed  Google Scholar 

  12. Stanghellini V, Cogliandro RF, De Giorgio R, et al. Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. Clin Gastroenterol Hepatol. 2005;3:449–58.

    Article  PubMed  Google Scholar 

  13. Lindberg G, Iwarzon M, Tornblom H. Clinical features and long-term survival in chronic intestinal pseudo-obstruction and enteric dysmotility. Scand J Gastroenterol. 2009;44:692–9.

    Article  PubMed  Google Scholar 

  14. Antonucci A, Fronzoni L, Cogliandro L, et al. Chronic intestinal pseudo-obstruction. World J Gastroenterol. 2008;14:2953–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Rao SSC, Parkman H, McCallum R. Handbook of Gastrointestinal Motility and Functional Disorders. SLACK Incorporated: Thorofare; 2015.

    Google Scholar 

  16. De Giorgio R, Camilleri M. Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil. 2004;16:515–31.

    Article  PubMed  Google Scholar 

  17. Lee H, Park S, Oh JT, et al. Oral pyridostigmine-responsive visceral myopathy with ACTG2 mutations: a case series. J Pediatr Gastroenterol Nutr. 2019;68:e16–7.

    Article  PubMed  Google Scholar 

  18. Joly F, Amiot A, Coffin B, et al. Chronic intestinal pseudo-obstruction. Gastroenterol Clin Biol. 2006;30:975–85.

    Article  PubMed  Google Scholar 

  19. Yamanaka Y, Sakakibara R, Asahina M, et al. Chronic intestinal pseudo-obstruction as the initial feature of pure autonomic failure. J Neurol Neurosurg Psychiatry. 2006;77. England:800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chronic intestinal pseudo-obstruction - UpToDate, 2019.

  21. Man BL, Fu YP. Intestinal pseudo-obstruction as a presenting symptom of Guillain-Barre syndrome. BMJ Case Rep. 2014;2014.pii: bcr2014205155. https://doi.org/10.1136/bcr-2014-205155

  22. Yarze JC, Lenihan MW, Soule TI, et al. Treatment of colon pseudo-obstruction in Guillain-Barre syndrome. Am J Gastroenterol. 2001;96:3470–1.

    CAS  PubMed  Google Scholar 

  23. Sekino Y, Inamori M, Yamada E, et al. Characteristics of intestinal pseudo-obstruction in patients with mitochondrial diseases. World J Gastroenterol. 2012;18:4557–62.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Pelizzo G, Villanacci V, Salemme M, et al. Intestinal pseudo-obstruction due to small bowel alpha-actin deficiency in a child with Ehlers-Danlos syndrome. Tech Coloproctol. 2013;17:673–4.

    Article  CAS  PubMed  Google Scholar 

  25. McFarlane IM, Bhamra MS, Kreps A, et al. Gastrointestinal Manifestations of Systemic Sclerosis. Rheumatology (Sunnyvale). 2018;8(1):235

  26. Blondon H, Polivka M, Joly F, et al. Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE). Gastroenterol Clin Biol. 2005;29:773–8.

    Article  PubMed  Google Scholar 

  27. Lindberg G, Törnblom H, Iwarzon M, et al. Full-thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dysmotility. 2009;58(8):1084–90

  28. Knowles CH, Silk DB, Darzi A, et al. Deranged smooth muscle alpha-actin as a biomarker of intestinal pseudo-obstruction: a controlled multinational case series. Gut. 2004;53:1583–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. De Giorgio R, Guerrini S, Barbara G, et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology. 2004;126:1872–83.

    Article  PubMed  Google Scholar 

  30. Gerl A, Storck M, Schalhorn A, et al. Paraneoplastic chronic intestinal pseudoobstruction as a rare complication of bronchial carcinoid. Gut. 1992;33:1000–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Sutton I, Winer J, Rowlands D, et al. Limbic encephalitis and antibodies to Ma2: a paraneoplastic presentation of breast cancer. J Neurol Neurosurg Psychiatry. 2000;69:266–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Lee HR, Lennon VA, Camilleri M, et al. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol. 2001;96:373–9.

    Article  CAS  PubMed  Google Scholar 

  33. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543–54.

    Article  CAS  PubMed  Google Scholar 

  34. Smith VV, Gregson N, Foggensteiner L, et al. Acquired intestinal aganglionosis and circulating autoantibodies without neoplasia or other neural involvement. Gastroenterology. 1997;112:1366–71.

    Article  CAS  PubMed  Google Scholar 

  35. Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85:838–54.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Schappi MG, Smith VV, Milla PJ, et al. Eosinophilic myenteric ganglionitis is associated with functional intestinal obstruction. Gut. 2003;52:752–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Hall KE, Wiley JW. Neural injury, repair and adaptation in the GI tract. I. New insights into neuronal injury: a cautionary tale. Am J Phys. 1998;274:G978–83.

    CAS  Google Scholar 

  38. De Giorgio R BE, Bianco F, Cogliandro, R VU, Caio G. Chronic intestinal pseudo-obstruction: A. Neuropathological approach. In: Sakamoto C, ed. Functional and GI motility disorders. Frontiers. of Gastrointestinal Research. 33, 2014:45–54.

  39. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Coulie B, Szarka LA, Camilleri M, et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology. 2000;119:41–50.

    Article  CAS  PubMed  Google Scholar 

  41. De Giorgio R, Barbara G, Stanghellini V, et al. Reduced Bcl-2 expression in the enteric nervous system (ENS) as a marker for neural degeneration in patients with gastrointestinal motor disorders (GIMD). Gastroenterology. 2000;118:A867.

    Article  Google Scholar 

  42. Smith VV, Lake BD, Kamm MA, et al. Intestinal pseudo-obstruction with deficient smooth muscle alpha-actin. Histopathology. 1992;21:535–42.

    Article  CAS  PubMed  Google Scholar 

  43. Bashashati M, McCallum RW. Is Interstitial Cells of Cajal–opathy Present in Gastroparesis? J Neurogastroenterol Motil. 2015;21:486–93.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Isozaki K, Hirota S, Miyagawa J, et al. Deficiency of c-kit+ cells in patients with a myopathic form of chronic idiopathic intestinal pseudo-obstruction. Am J Gastroenterol. 1997;92:332–4.

    CAS  PubMed  Google Scholar 

  45. Boeckxstaens GE, Rumessen JJ, de Wit L, et al. Abnormal distribution of the interstitial cells of cajal in an adult patient with pseudo-obstruction and megaduodenum. Am J Gastroenterol. 2002;97:2120–6.

    Article  PubMed  Google Scholar 

  46. •• Keller J, Bassotti G, Clarke J, et al. Expert consensus document: advances in the diagnosis and classification of gastric and intestinal motility disorders. Nat Rev Gastroenterol Hepatol. 2018;15:291–308. Current and comprehensive expert consensus review on the advances in the diagnosis and classification of gastrointestinal motility disorders.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Di Nardo G, Karunaratne TB, Frediani S, et al. Chronic intestinal pseudo-obstruction: Progress in management? Neurogastroenterol Motil. 2017;29(12). https://doi.org/10.1111/nmo.13231

  48. Malagelada C, Karunaratne TB, Accarino A, et al. Comparison between small bowel manometric patterns and full-thickness biopsy histopathology in severe intestinal dysmotility. Neurogastroenterol Motil. 2018;30.

  49. Stanghellini V, Camilleri M, Malagelada JR. Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings. Gut. 1987;28:5–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Bassotti G, Bologna S, Ottaviani L, et al. Intestinal manometry: who needs it? Gastroenterol Hepatol Bed Bench. 2015;8:246–52.

    PubMed  PubMed Central  Google Scholar 

  51. Lindberg G, Tornblom H, Iwarzon M, et al. Full-thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dysmotility. Gut. 2009;58:1084–90.

    Article  CAS  PubMed  Google Scholar 

  52. Patcharatrakul T, Gonlachanvit S. Technique of functional and motility test: how to perform antroduodenal manometry. J Neurogastroenterol Motil. 2013;19:395–404.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Comparison between small bowel manometric patterns and full-thickness biopsy histopathology in severe intestinal dysmotility - Malagelada - 2018 - Neurogastroenterology & Motility - Wiley Online Library. 2019.

  54. Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27:160–74.

    Article  CAS  PubMed  Google Scholar 

  55. Malagelada C, Malagelada JR. Small bowel motility. Curr Gastroenterol Rep. 2017;19:26.

    Article  PubMed  Google Scholar 

  56. Lindberg G. High-resolution manometry changes our views of gastrointestinal motility. Neurogastroenterol Motil. 2013;25:780–2.

    Article  CAS  PubMed  Google Scholar 

  57. Farmer AD, Scott SM, Hobson AR. Gastrointestinal motility revisited: the wireless motility capsule. United European Gastroenterol J. 2013;1:413–21.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Adler SN, Metzger YC. PillCam COLON capsule endoscopy: recent advances and new insights. Ther Adv Gastroenterol. 2011;4:265–8.

    Article  Google Scholar 

  59. Odille F, Menys A, Ahmed A, et al. Quantitative assessment of small bowel motility by nonrigid registration of dynamic MR images. Magn Reson Med. 2012;68:783–93.

    Article  PubMed  Google Scholar 

  60. Menys A, Butt S, Emmanuel A, et al. Comparative quantitative assessment of global small bowel motility using magnetic resonance imaging in chronic intestinal pseudo-obstruction and healthy controls. Neurogastroenterol Motil. 2016;28:376–83.

    Article  CAS  PubMed  Google Scholar 

  61. Fuyuki A, Ohkubo H, Higurashi T, et al. Clinical importance of cine-MRI assessment of small bowel motility in patients with chronic intestinal pseudo-obstruction: a retrospective study of 33 patients. J Gastroenterol. 2017;52:577–84.

    Article  PubMed  Google Scholar 

  62. Ohkubo H, Kessoku T, Fuyuki A, et al. Assessment of small bowel motility in patients with chronic intestinal pseudo-obstruction using cine-MRI. Am J Gastroenterol. 2013;108:1130–9.

    Article  PubMed  Google Scholar 

  63. Iwarzon M, Gardulf A, Lindberg G. Health care use in patients with chronic intestinal dysmotility before and after introducing a specialized day-care unit. Clin Gastroenterol Hepatol. 2008;6:893–8.

    Article  PubMed  Google Scholar 

  64. Silk DB. Chronic idiopathic intestinal pseudo-obstruction: the need for a multidisciplinary approach to management. Proc Nutr Soc. 2004;63. England:473–80.

    Article  CAS  PubMed  Google Scholar 

  65. Tomomasa T, Kuroume T, Arai H, et al. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci. 1986;31:157–61.

    Article  CAS  PubMed  Google Scholar 

  66. Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther. 2004;19:687–94.

    Article  CAS  PubMed  Google Scholar 

  67. Abrahamsson H. Treatment options for patients with severe gastroparesis. Gut. 2007;56:877–83.

    Article  PubMed  PubMed Central  Google Scholar 

  68. NCATS Inxight: Drugs — CAMICINAL, 2019.

  69. Deloose E, Depoortere I, de Hoon J, et al. Manometric evaluation of the motilin receptor agonist camicinal (GSK962040) in humans. Neurogastroenterol Motil. 2018;30(1). https://doi.org/10.1111/nmo.13173

  70. Hobson R, Farmer AD, Dewit OE, et al. The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial. Neurogastroenterol Motil. 2015;27:1629–37.

    Article  CAS  PubMed  Google Scholar 

  71. Chapman MJ, Deane AM, O’Connor SL, et al. The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. Crit Care. 2016;20:232.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Müller T, Nogueiras R, Andermann M, et al. Ghrelin. Mol Metab. 2015;4:437–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Mosinska P, Zatorski H, Storr M, et al. Future treatment of constipation-associated fisorders: role of relamorelin and other ghrelin receptor agonists. J Neurogastroenterol Motil. 2017;23:171–9.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Zatorski H, Mosinska P, Storr M, et al. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease. J Physiol Pharmacol. 2017;68:797–805.

    CAS  PubMed  Google Scholar 

  75. A safety and efficacy study of relamorelin in diabetic gastroparesis 01 - Full Text View - ClinicalTrials.gov. 2019.

  76. Van der Ploeg L, Laken H, Sharma S, et al. Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131. Life Sci. 2014;109:20–9.

    Article  CAS  PubMed  Google Scholar 

  77. Sajid MS, Hebbar M, Baig MK, et al. Use of prucalopride for chronic constipation: a systematic review and meta-analysis of published randomized, controlled trials. J Neurogastroenterol Motil. 2016;22. Korea (South):412–22.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Emmanuel AV, Kamm MA, Roy AJ, et al. Randomized clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther. 2012;35:48–55.

    Article  CAS  PubMed  Google Scholar 

  79. Camilleri M, Malagelada JR, Abell TL, et al. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology. 1989;96:704–12.

    CAS  PubMed  Google Scholar 

  80. Abell TL, Camilleri M, DiMagno EP, et al. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci. 1991;36:616–20.

    Article  CAS  PubMed  Google Scholar 

  81. Reddymasu SC, McCallum RW. Pharmacotherapy of gastroparesis. Expert Opin Pharmacother. 2009;10:469–84.

    Article  CAS  PubMed  Google Scholar 

  82. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102:2036–45.

    Article  CAS  PubMed  Google Scholar 

  83. Buffery PJ, Strother RM. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. N Z Med J. 2015;128:66–74.

    PubMed  Google Scholar 

  84. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325:1461–7.

    Article  CAS  PubMed  Google Scholar 

  85. Verne GN, Eaker EY, Hardy E, et al. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci. 1995;40:1892–901.

    Article  CAS  PubMed  Google Scholar 

  86. Edmunds MC, Chen JD, Soykan I, et al. Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther. 1998;12:167–74.

    Article  CAS  PubMed  Google Scholar 

  87. Fan JMG, Diaz J, Paez V, McCallum R. Pneumatosis cystoides intestinalis scleroderma: a case series. El Paso Physician. 2017;40: El Paso County Medical Society:6–9.

    Google Scholar 

  88. Mitsuyoshi Y, Takakura K, Kobayashi T, et al. Chronic intestinal pseudo-obstruction with pneumatosis cystoides intestinalis in a patient with systemic sclerosis: a case report. Medicine (Baltimore). 2019;98:e15480.

    Article  Google Scholar 

  89. Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16:2978–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Rosson RS, Yesner R. Peroral duodenal biopsy in progressive systemic sclerosis. N Engl J Med. 1965;272:391–4.

    Article  CAS  PubMed  Google Scholar 

  91. Law NM, Bharucha AE, Undale AS, et al. Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans. Am J Physiol Gastrointest Liver Physiol. 2001;281:G1228–37.

    Article  CAS  PubMed  Google Scholar 

  92. Parthasarathy G, Ravi K, Camilleri M, et al. Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders. Neurogastroenterol Motil. 2015;27:1736–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Calvet X, Martinez JM, Martinez M. Repeated neostigmine dosage as palliative treatment for chronic colonic pseudo-obstruction in a patient with autonomic paraneoplastic neuropathy. Am J Gastroenterol. 2003;98. United States:708–9.

    Article  PubMed  Google Scholar 

  94. Lee BH, Kim N, Kang SB, et al. Two Cases of Chronic Idiopathic Intestinal Pseudo-obstruction with Different Clinical Features. J Neurogastroenterol Motil. 2010;16:83–9.

    Article  PubMed  PubMed Central  Google Scholar 

  95. O’Dea CJ, Brookes JH, Wattchow DA. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Color Dis. 2010;12:540–8.

    Article  Google Scholar 

  96. Small intestinal bacterial overgrowth: management - UpToDate, 2019.

  97. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007;3:112–22.

    Google Scholar 

  98. Uchida K, Otake K, Inoue M, et al. Chronic intestinal pseudo-obstruction due to lymphocytic intestinal leiomyositis: case report and literature review. Intractable Rare Dis Res. 2012;1:35–9.

    PubMed  PubMed Central  Google Scholar 

  99. Badari A, Farolino D, Nasser E, et al. A novel approach to paraneoplastic intestinal pseudo-obstruction. Support Care Cancer. 2012;20:425–8.

    Article  PubMed  Google Scholar 

  100. Ohkubo H, Fuyuki A, Arimoto J, et al. Efficacy of percutaneous endoscopic gastro-jejunostomy (PEG-J) decompression therapy for patients with chronic intestinal pseudo-obstruction (CIPO). Neurogastroenterol Motil. 2017;29(12). https://doi.org/10.1111/nmo.13127

  101. Pironi L, Arends J, Baxter J, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr. 2015;34:171–80.

    Article  PubMed  Google Scholar 

  102. De Giorgio R, Cogliandro RF, Barbara G, et al. Chronic intestinal pseudo-obstruction: clinical features, diagnosis, and therapy. Gastroenterol Clin N Am. 2011;40:787–807.

    Article  Google Scholar 

  103. Scolapio JS, Ukleja A, Bouras EP, et al. Nutritional management of chronic intestinal pseudo-obstruction. J Clin Gastroenterol. 1999;28:306–12.

    Article  CAS  PubMed  Google Scholar 

  104. Billiauws L, Corcos O, Joly F. Dysmotility disorders: a nutritional approach. Curr Opin Clin Nutr Metab Care. 2014;17:483–8.

    Article  PubMed  Google Scholar 

  105. Sabbagh C, Amiot A, Maggiori L, et al. Non-transplantation surgical approach for chronic intestinal pseudo-obstruction: analysis of 63 adult consecutive cases. Neurogastroenterol Motil. 2013;25:e680–6.

    CAS  PubMed  Google Scholar 

  106. De Giorgio R, Ricciardiello L, Naponelli V, et al. Chronic intestinal pseudo-obstruction related to viral infections. Transplant Proc. 2010;42:9–14.

    Article  PubMed  Google Scholar 

  107. Munoz MT, Solis Herruzo JA. Chronic intestinal pseudo-obstruction. Rev Esp Enferm Dig. 2007;99:100–11.

    Article  CAS  PubMed  Google Scholar 

  108. Cogliandro RF, De Giorgio R, Barbara G, et al. Chronic intestinal pseudo-obstruction. Best Pract Res Clin Gastroenterol. 2007;21:657–69.

    Article  PubMed  Google Scholar 

  109. Janssen P, Verschueren S, Ly HG, et al. Intragastric pressure during food intake: a physiological and minimally invasive method to assess gastric accommodation. Neurogastroenterol Motil. 2011;23:316–22 e153–4.

    Article  CAS  PubMed  Google Scholar 

  110. Rao SS, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil. 2011;23:8–23.

    Article  CAS  PubMed  Google Scholar 

  111. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Am J Gastroenterol. 2017;112:775–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Barros LL, Farias AQ, Rezaie A. Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: prevalence, diagnosis and treatment. World J Gastroenterol. 2019;25:4414–26.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol. 2011;25(Suppl B):16b–21b.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Knowles CH, De Giorgio R, Kapur RP, et al. The London classification of gastrointestinal neuromuscular pathology: report on behalf of the Gastro 2009 International Working Group. Gut. 2010;59:882–7.

    Article  PubMed  Google Scholar 

  115. Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108:18–37 quiz 38.

    Article  CAS  PubMed  Google Scholar 

  116. Emmanuel AV, Kamm MA, Roy AJ, Kerstens R, Vandeplassche L. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther. 2012;35:48–55.

    Article  CAS  PubMed  Google Scholar 

  117. Lipton AB, Knauer CM. Pseudo-obstruction of the bowel. Therapeutic trial of metoclopramide. Am J Dig Dis. 1977;22:263–5.

    Article  CAS  PubMed  Google Scholar 

  118. Sorhaug S, Steinshamn SL, Waldum HL. Octreotide treatment for paraneoplastic intestinal pseudo-obstruction complicating SCLC. Lung Cancer. 2005;48:137–40.

    Article  PubMed  Google Scholar 

  119. O'Dea CJ, Brookes JH, Wattchow DA. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Color Dis. 2010;12:540–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, GI Motility Training and Research, Texas Tech University Health Sciences Center El Paso, 4800 Alberta, MSC 41007, El Paso, TX, 79905, USA

    Zorisadday Gonzalez

  2. Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, 4800 Alberta, MSC 41007, El Paso, TX, 79905, USA

    Richard McCallum

Authors
  1. Zorisadday Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard McCallum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zorisadday Gonzalez.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gonzalez, Z., McCallum, R. Small Bowel Dysmotility, Pseudoobstruction, and Functional Correlation with Histopathology: Lessons Learned. Curr Gastroenterol Rep 22, 14 (2020). https://doi.org/10.1007/s11894-020-0748-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-020-0748-8

Keywords

Search

Navigation